Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

The promise of cell-based therapies in diabetes: A review of mesenchymal stem cell applications and trials.

Li C., Wang S., Jiang J., Fu W., Zeng J.

Clinical Trial on Type 2 Diabetes, Immune Modulation, Autoimmune Research, published in Biochimie (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Biochimie (2025)
Country
France
Reported sample size
—
Source database
PubMed
PMID
40639683
DOI
10.1016/j.biochi.2025.07.011

Abstract (original English)

Diabetes mellitus, characterized by chronic hyperglycemia, presents a major global health burden with rising incidence worldwide. Current therapies often fail to achieve sustained glycemic control or halt disease progression, necessitating innovative strategies that target both metabolic dysfunction and autoimmune mechanisms in diabetes. Mesenchymal stem cells (MSCs) have garnered significant attention as a multifaceted therapeutic option, owing to their unique dual capabilities: tissue repair (via differentiation potential and paracrine effects) and immunomodulation (through cytokine secretion and immune cell regulation). This review comprehensively examines the therapeutic potential of MSCs in diabetes, covering: (1) mechanistic insights into how MSCs restore pancreatic β-cell function and mitigate insulin resistance; (2) preclinical evidence supporting their efficacy in both type 1 and type 2 diabetes models; and (3) critical analysis of ongoing clinical trials, including routes of administration, safety profiles, and metabolic outcomes. While promising results have been demonstrated in early-phase trials, we also discuss key challenges such as cell survival, standardization of protocols, and long-term therapeutic durability. By bridging current knowledge gaps with clinical translation needs, this review aims to provide a balanced perspective on MSC-based therapies for diabe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsAnimalsClinical Trials as TopicDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Cell- and Tissue-Based TherapyInsulin-Secreting Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research